PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshead and neck neoplasms
MeSH D006258 - head and neck neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009371:Neoplasms by site
0 Companies
0 Drugs
Success rate
D006258: 
Head and neck neoplasms
56 Companies
8 Drugs
$
Success rate
D000077195:Squamous cell carcinoma of head and neck
2 Companies
2 Drugs
$
Success rate
D004938:Esophageal neoplasms
34 Companies
3 Drugs
$
Success rate
D005153:Facial neoplasms
0 Companies
0 Drugs
Success rate
D009062:Mouth neoplasms
0 Companies
0 Drugs
Success rate
D010039:Otorhinolaryngologic neoplasms
0 Companies
0 Drugs
Success rate
D010282:Parathyroid neoplasms
15 Companies
1 Drug
$
Success rate
D013964:Thyroid neoplasms
46 Companies
10 Drugs
$
Success rate
D014134:Tracheal neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaFluorouracil Adrucil  1991-10-18   
Docetaxel Docetaxel  2015-09-16   
Docetaxel Docetaxel Teva  2010-01-26   
Docetaxel Docetaxel Teva Pharma  2011-01-21   
Fluorouracil Fluorouracil  2000-01-27   
Novast LaboratoriesFluorouracil Fluorouracil  2019-12-12   
Docetaxel Docetaxel  2017-08-31   
PadagisPilocarpine Pilocarpine  2004-11-16   
Taro PharmaceuticalFluorouracil Fluorouracil  2003-11-05   
IngenusDocetaxel Docetaxel 2036-03-14 2022-11-22   
MylanDocetaxel Docetaxel  2023-05-11   
Docetaxel Docetaxel Mylan  2012-01-31   
Fluorouracil Fluorouracil  2015-04-20   
SandozDocetaxel Docetaxel  2011-06-29   
Fluorouracil Fluorouracil  2011-05-02   
Pilocarpine Isopto Carpine  2010-06-22   
AbbViePilocarpine Vuity 2039-04-24 2021-10-28   
SanofiDocetaxel Taxotere  1996-05-14   
Bausch Health CompaniesFluorouracil Carac  2000-10-27   
Fluorouracil Efudex  1982-01-01   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
70%
111/158
Phase 2
33%
80/242
Phase 3
21%
22/107
Approved: 8Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Docetaxel
Mylan
Docetaxel
AbbVie
BUDIGALIMAB,
GILORALIMAB,
REVDOFILIMAB
Sanofi
Docetaxel,
Transplatin,
Antithrombin iii,
Tirapazamine,
Retinol
Bausch Health Companies
Fluorouracil
Merck Sharp & Dohme
Cetuximab,
Transplatin,
Albumin,
Antithrombin iii,
Bempegaldesleukin,
Sotatercept,
Feladilimab,
Epacadostat,
Fenretinide,
Sodium chloride,
PEPINEMAB,
Nc410,
Bca101
Pfizer
Docetaxel,
Transplatin,
Sasanlimab,
Gedatolisib
Eli Lilly
Vinblastine,
Transplatin,
Aglatimagene besadenovec,
Calcium dobesilate,
Methylcobalamin,
Sodium chloride,
CIXUTUMUMAB,
LITRONESIB,
PREXASERTIB,
Retinol,
Ly3295668
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use